Structural Prediction of Peptide-MHC Binding Modes
- PMID: 35298818
- DOI: 10.1007/978-1-0716-1855-4_13
Structural Prediction of Peptide-MHC Binding Modes
Abstract
The immune system is constantly protecting its host from the invasion of pathogens and the development of cancer cells. The specific CD8+ T-cell immune response against virus-infected cells and tumor cells is based on the T-cell receptor recognition of antigenic peptides bound to class I major histocompatibility complexes (MHC) at the surface of antigen presenting cells. Consequently, the peptide binding specificities of the highly polymorphic MHC have important implications for the design of vaccines, for the treatment of autoimmune diseases, and for personalized cancer immunotherapy. Evidence-based machine-learning approaches have been successfully used for the prediction of peptide binders and are currently being developed for the prediction of peptide immunogenicity. However, understanding and modeling the structural details of peptide/MHC binding is crucial for a better understanding of the molecular mechanisms triggering the immunological processes, estimating peptide/MHC affinity using universal physics-based approaches, and driving the design of novel peptide ligands. Unfortunately, due to the large diversity of MHC allotypes and possible peptides, the growing number of 3D structures of peptide/MHC (pMHC) complexes in the Protein Data Bank only covers a small fraction of the possibilities. Consequently, there is a growing need for rapid and efficient approaches to predict 3D structures of pMHC complexes. Here, we review the key characteristics of the 3D structure of pMHC complexes before listing databases and other sources of information on pMHC structures and MHC specificities. Finally, we discuss some of the most prominent pMHC docking software.
Keywords: Databases; Docking algorithms; Immune system; Ligand binding; Major histocompatibility complex; Molecular mechanics; Peptide antigen; Peptide docking; T-cell receptor.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Hansen TH, Bouvier M (2009) MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 9:503–513. https://doi.org/10.1038/nri2575 - DOI - PubMed
-
- Hewitt EW (2003) The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 110:163–169. https://doi.org/10.1046/j.1365-2567.2003.01738.x - DOI - PubMed - PMC
-
- Jones EY, Fugger L, Strominger JL, Siebold C (2006) MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 6:271–282. https://doi.org/10.1038/nri1805 - DOI - PubMed
-
- Roche PA, Furuta K (2015) The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol 15:203–216. https://doi.org/10.1038/nri3818 - DOI - PubMed - PMC
-
- Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74. https://doi.org/10.1126/science.aaa4971 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
